Fitness6 months ago
Teprotumumab Gives Lasting Relief from Thyroid Eye Disease
Nearly 2 years after their final transfusion with the IGF-IR inhibitor teprotumumab (Tepezza), 82% of patients with thyroid eye disease did not need further treatment for...
